Lee Nisley Newcomer
CIK: 0001788981
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 5, 2026CHRS
Coherus Oncology, Inc.
Award(A)Direct30K shares- - Jun 4, 2026MYGN
MYRIAD GENETICS INC
Award(A)Direct59.7K shares- - Jun 12, 2025CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
112K shares- - Jun 5, 2025MYGN
MYRIAD GENETICS INC
Award(A)Direct49.8K shares-
1-4 of 4 transactions
About Newcomer Lee Nisley
Newcomer Lee Nisley (SEC CIK 0001788981) files insider reports with the SEC as Director of Coherus Oncology, Inc. (CHRS) and Director of MYRIAD GENETICS INC (MYGN).
Signal8 holds 4 ownership filings by Newcomer Lee Nisley, all Form 4s, filed between Jun 6, 2025 and Jun 9, 2026. Those filings report 4 transactions, from Jun 5, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Newcomer Lee Nisley's filings is in SALT LAKE CITY, UT.
Recent filings by Newcomer Lee Nisley
Other insiders filing for Coherus Oncology, Inc. (CHRS)
- Satvat Ali J., Director
- Karachun Rita A, Director
- Ryan Michael Lee, Director
- O'Donnell-Tormey Jill, Director
- Wahlstrom Mats, Director
- Newton Charles W., Director